Latest chemotherapy Stories
GILBERT, Ariz., Aug.
Simvastatin Could Boost Effectiveness of Chemotherapy Drug Pemetrexed DALLAS (PRWEB) August 15, 2014 A team of Korean researchers has found that a drug
Company Strengthens Intellectual Property Protection in Additional Global Market DALLAS and NEW YORK, Aug. 14, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.
Patented Technology Enables Accurate Delivery of a Chemotherapeutic Drug to Targeted Tumor Cells, Reducing Drug-related Toxicity without Sacrificing Therapeutic Impact SYDNEY, Aug.
Previous vaccination lowers the risk of shingles among older patients undergoing chemotherapy by 42 percent PASADENA, Calif., Aug.
DALLAS and NEW YORK, July 30, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.
Cancer Research UK scientists at Barts Cancer Institute have found that targeting a molecule in blood vessels can make cancer therapy significantly more effective.
A curcumin analog and a drug normally used to prevent rejection of organ transplants may make mesothelioma cells more susceptible to chemotherapy. Raleigh, NC
The Mesothelioma Compensation Center is urging a diagnosed victim of mesothelioma, or their family members to call them at 866-714-6466 for instant access to the nation's most skilled mesothelioma
Capital Institute for Neurosciences Begins Clinical Trial Delivering Chemotherapy Directly to Brain Tumors Starting with Incision in Leg Hopewell, NJ (PRWEB)
Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...
- totally perplexed and mixed up.